The impact of diabetes on tuberculosis treatment outcomes: A systematic review

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Baker, Meghan A ^a,b   Harries, Anthony D ^c,d   Jeon, Christie Y ^b,e   Hart, Jessica E ^f   Kapur, Anil ^g   Lönnroth, Knut ^h   Ottmani, Salah Eddine ^h   Goonesekera, Sunali D ^b   Murray, Megan B ^b,i  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e Howard Hughes Medical Institute   (United States)

^f BROWN UNIVERSITY   (United States)

^g World Diabetes Foundation   (Denmark)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; DEATH; DIABETES MELLITUS; DRUG RESISTANT TUBERCULOSIS; EVIDENCE BASED MEDICINE; GENETIC HETEROGENEITY; HUMAN; META ANALYSIS; RECURRENCE RISK; RELAPSE; RISK FACTOR; SPUTUM CULTURE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; MORTALITY; SURVIVAL;

ANTITUBERCULAR AGENTS; DIABETES COMPLICATIONS; HUMANS; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 79959733115     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-81     Document Type: Article

References (71)

1. Lonnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 2008, 29:481-491. 10.1055/s-0028-1085700, 18810682.
2. World Heath Organization Global tuberculosis control 2009: epidemiology, strategy, financing. 2010, Geneva, Switzerland, WHO/HTM/TB/2009.411, World Heath Organization., http://www.who.int/tb/publications/global_report/2009/en
3. Ponce-De-Leon A, Garcia-Garcia Md Mde L, Garcia-Sancho MC, Gomez-Perez FJ, Valdespino-Gomez JL, Olaiz-Fernandez G, Rojas R, Ferreyra-Reyes L, Cano-Arellano B, Bobadilla M, Small PM, Sifuentes-Osornio J. Tuberculosis and diabetes in southern Mexico. Diabetes Care 2004, 27:1584-1590. 10.2337/diacare.27.7.1584, 15220232.
4. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008, 5:e152. 10.1371/journal.pmed.0050152, 2459204, 18630984.
5. Stevenson CR, Forouhi NG, Roglic G, Williams BG, Lauer JA, Dye C, Unwin N. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007, 7:234. 10.1186/1471-2458-7-234, 2001194, 17822539.
6. Kim SJ, Hong YP, Lew WJ, Yang SC, Lee EG. Incidence of pulmonary tuberculosis among diabetics. Tuber Lung Dis 1995, 76:529-533. 10.1016/0962-8479(95)90529-4, 8593374.
7. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009, 9:737-746. 10.1016/S1473-3099(09)70282-8, 2945809, 19926034.
8. International Diabetes Federation Diabetes Factsand Figures 2009. Diabetes Prevalence. 2009, International Diabetes Federation., http://www.idf.org/diabetes-prevalence
9. Restrepo BI. Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin Infect Dis 2007, 45:436-438. 10.1086/519939, 2900315, 17638190.
10. Restrepo BI, Fisher-Hoch SP, Crespo JG, Whitney E, Perez A, Smith B, McCormick JB, . Nuevo Santander Tuberculosis Trackers Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect 2007, 135:483-491. 10.1017/S0950268806006935, 2870584, 16863600, Nuevo Santander Tuberculosis Trackers.
11. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, Nelwan RH, Parwati I, van der Meer JW, van Crevel R. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007, 45:428-435. 10.1086/519841, 17638189.
12. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009, 80:634-639. 2750857, 19346391.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012. 10.1001/jama.283.15.2008, 10789670.
14. World Health Organization Treatment of tuberculosis. Guidelines for National Programmmes. 2010, Geneva, Switzerland, WHO/CDS/TB 2003.313, World Health Organization., http://whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.313_eng.pdf
15. World Health Organization Treatment of tuberculosis guidelines fourth edition. 2010, Geneva, Switzerland, WHO/HTM/TB/2009.402, World Health Organization., http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf
16. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001, 5:213-215. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association.
17. World Health Organization Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. 2010, Geneva, Switzerland: WHO, World Health Organization., http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
19. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987, 9:1-30.
20. Cochran WG. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558. 10.1002/sim.1186, 12111919.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
23. Jeon CY, Harries AD, Baker MA, Hart JE, Kapur A, Lönnroth K, Ottmani SE, Goonesekera S, Murray MB. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health 2010, 15:1300-1314. 10.1111/j.1365-3156.2010.02632.x, 20958887.
24. Oluboyo PO, Erasmus RT. The significance of glucose intolerance in pulmonary tuberculosis. Tubercle 1990, 71:135-138. 10.1016/0041-3879(90)90010-6, 2219464.
25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101. 10.2307/2533446, 7786990.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 2127453, 9310563.
27. StataCorp. Stata Statistical Software: Release 10. College Station (Texas): StataCorp LP 2007, StataCorp. Stata.
28. Ambrosetti M, Besozzi G, Codecasa LR, Farris B, Nutini S, Saini L, Casali L, Nardini S, Migliori GB. The Italian AIPO study on tuberculosis treatment results, report 1995 National AIPO "Tuberculosis" Study Group. Monaldi Arch Chest Dis 1999, 54:49-54.
29. Ambrosetti M, Besozzi G, Farris B, Nutini S, Saini L, Casali L, Pretto P, Orani G, Calabro S, Migliori GB. The Italian AIPO study on tuberculosis treatment results, report 1996. National AIPO "Tuberculosis" Study Group. Associazione Italiana Pneumologi Ospedalieri. Monaldi Arch Chest Dis 1999, 54:237-241.
30. Ambrosetti M, Besozzi G, Codecasa LR, Farris B, Nutini S, Saini L, Casali L, Nardini S, Migliori GB. The Italian AIPO study on tuberculosis treatment results, report 1997. National AIPO "Tuberculosis" Study Group. Monaldi Arch Chest Dis 1999, 54:407-412.
31. Anunnatsiri S, Chetchotisakd P, Wanke C. Factors associated with treatment outcomes in pulmonary tuberculosis in Northeastern Thailand. Southeast Asian J Trop Med Public Health 2005, 36:324-330.
32. Banu Rekha VV, Balasubramanian R, Swaminathan S, Ramachandran R, Rahman F, Sundaram V, Thyagarajan K, Selvakumar N, Adhilakshmi AR, Iliayas S, Narayanan PR. Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors. Indian J Med Res 2007, 126:452-458.
33. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001, 120:1514-1519. 10.1378/chest.120.5.1514, 11713128.
34. Blanco JAG, Toste IS, Fernandez ML, Morales RG, Alvarez RF, Cuadrado GR, Gonzalvez AM, Martin IJG. Tobacco smoking and sputum smear conversion in pulmonary tuberculosis. Medicina Clinica 2007, 128:565-568. 10.1157/13101612, 17462193.
35. Centis R, Ianni A, Migliori GB. Evaluation of tuberculosis treatment results in Italy, report 1998. Tuberculosis section of the National AIPO Study Group on Infectious Disease and the SMIRA Group. Monaldi Arch Chest Dis 2000, 55:293-298.
36. Centis R, Migliori GB. Evaluation of tuberculosis treatment results in Italy, report 1999. Monaldi Arch Chest Dis 2002, 57:297-305.
37. Chiang CY, Lee JJ, Yu MC, Enarson DA, Lin TP, Luh KT. Tuberculosis outcomes in Taipei: factors associated with treatment interruption for 2 months and death. Int J Tuberc Lung Dis 2009, 13:105-111.
38. Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis 2002, 6:1114-1117.
39. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, Restrepo BI, . Nuevo Santander Tuberculosis Trackers Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis 2008, 40:888-893. 10.1080/00365540802342372, 2887603, 18728934, Nuevo Santander Tuberculosis Trackers.
40. Guler M, Unsal E, Dursun B, Aydln O, Capan N. Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. Int J Clin Pract 2007, 61:231-235.
41. Hara H. From the aspects of complicated diseases. Kekkaku 1996, 71:47-56.
42. Hasibi M, Rasoulinejad M, Hosseini SM, Davari P, Sahebian A, Khashayar P. Epidemiological, clinical, laboratory findings, and outcomes of disseminated tuberculosis in Tehran, Iran. South Med J 2008, 101:910-913. 10.1097/SMJ.0b013e318180bcfd, 18708951.
43. Ito K, Wada M, Yoshiyama T, Ohmori M, Ogata H. Drug resistance in recurrent cases of tuberculosis. Kekkaku 2004, 79:461-467.
44. Kitahara Y, Ikeda A, Kajiki A, Maruyama M, Harada S, Harada Y, Takamoto M, Ishibashi T. An investigation on risk factors relating to the treatment difficulty in originally treated pulmonary tuberculosis cases. Kekkaku 1994, 69:503-511.
45. Kourbatova EV, Borodulin BE, Borodulina EA, del Rio C, Blumberg HM, Leonard MK. Risk factors for mortality among adult patients with newly diagnosed tuberculosis in Samara, Russia. Int J Tuberc Lung Dis 2006, 10:1224-1230.
46. Maalej S, Belhaoui N, Bourguiba M, Mahouachi R, Chtourou A, Taktak S, Fennira H, Slim L, Kheder AB, Drira I. Pulmonary tuberculosis and diabetes. A retrospective study of 60 patients in Tunisia. Presse Med 2009, 38:20-24. 10.1016/j.lpm.2008.05.011, 18771896.
47. Mboussa J, Monabeka H, Kombo M, Yokolo D, Yoka-Mbio A, Yala F. Course of pulmonary tuberculosis in diabetics. Rev Pneumol Clin 2003, 59:39-44.
48. Oursler KK, Moore RD, Bishai WR, Harrington SM, Pope DS, Chaisson RE. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002, 34:752-759. 10.1086/338784, 11850859.
49. Pina JM, Dominguez A, Alcaide J, Alvarez J, Camps N, Diez M, Godoy P, Jansá JM, Minquell S, Arias C. Excess mortality due to tuberculosis and factors associated to death in and annual cohort of patients diagnosed of tuberculosis. Rev Clin Esp 2006, 206:560-565. 10.1016/S0014-2565(06)72897-1, 17265572.
50. Singla R, Khan N, Al-Sharif N, Ai-Sayegh MO, Shaikh MA, Osman MM. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis 2006, 10:74-79.
51. Subhash HS, Ashwin I, Mukundan U, Danda D, John G, Cherian AM, Thomas K. Drug resistant tuberculosis in diabetes mellitus: a retrospective study from south India. Trop Doct 2003, 33:154-156.
52. Tatar D, Senol G, Alptekin S, Karakurum C, Aydin M, Coskunol I. Tuberculosis in diabetics: Features in an endemic area. Jpn J Infect Dis 62:423-427.
53. Vasankari T, Holmstrom P, Ollgren J, Liippo K, Kokki M, Ruutu P. Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study. BMC Public Health 2007, 7:291. 10.1186/1471-2458-7-291, 2099439, 17935630.
54. Wada M. The effectiveness of pyrazinamide-containing six-month short course chemotherapy. Kekkaku 2000, 75:665-673.
55. Wang PD, Lin RS. Drug-resistant tuberculosis in Taipei, 1996-1999. Am J Infect Control 2001, 29:41-47. 10.1067/mic.2001.110779, 11172317.
56. Wang CS, Yang CJ, Chen HC, Chuang SH, Chong IW, Hwang JJ, Huang MS. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009, 137:203-210. 10.1017/S0950268808000782, 18559125.
57. Zhang Q, Xiao H, Sugawara I. Tuberculosis complicated by diabetes mellitus at Shanghai Pulmonary Hospital, China. Jpn J Infect Dis 62:390-391.
58. World Heath Organization Global tuberculosis control: a short update to the 2009 report. 2010, Geneva, Switzerland, World Heath Organization., http://www.who.int/tb/country/data/download/en/index.html
59. Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002, 156:714-719. 10.1093/aje/kwf111, 12370159.
60. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006, 295:676-680. 10.1001/jama.295.6.676, 16467236.
61. Sterne JAC, Gavaghan D, Egger M. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000, 53:1119-1129. 10.1016/S0895-4356(00)00242-0, 11106885.
62. Bock NN, Jensen PA, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 2007, 196:S108-113. 10.1086/518661, 17624819.
63. Gregg EW, Gu Q, Cheng YJ, Venkat Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007, 147:149-155.
64. Saiki O, Negoro S, Tsuyuguchi I, Yamamura Y. Depressed immunological defense mechanisms in mice with experimentally induced diabetes. Infect Immun 1980, 28:127-131. 550901, 6966615.
65. Yamashiro S, Kawakami K, Uezu K, Kinjo T, Miyagi K, Nakamura K, Saito A. Lower expression of Th1-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis. Clin Exp Immunol 2005, 139:57-64. 10.1111/j.1365-2249.2005.02677.x, 1809276, 15606614.
66. Tsukaguchi K, Okamura H, Ikuno M, Kobayashi A, Fukuoka A, Takenaka H, Yamamoto C, Tokuyama T, Okamoto Y, Fu A, Yoshikawa M, Yoneda T, Narita N. The relation between diabetes mellitus and IFN-gamma, IL-12 and IL-10 productions by CD4+ alpha beta T cells and monocytes in patients with pulmonary tuberculosis. Kekkaku 1997, 72:617-622.
67. Al-Attiyah RJ, Mustafa AS. Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis bacilli Calmette-Guerin (BCG)-vaccinated healthy subjects. Clin Exp Immunol 2009, 158:64-73. 10.1111/j.1365-2249.2009.04000.x, 2759060, 19737232.
68. Stalenhoef JE, Alisjahbana B, Nelwan EJ, van der Ven-Jongekrijg, Ottenhoff THM, van der Meer JWM, Nelwan RH, Netea MG, van Crevel R. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis 2008, 27:97-103. 10.1007/s10096-007-0395-0, 17962984.
69. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 2010, 54:1068-1074. 10.1128/AAC.00447-09, 2825975, 20038625.
70. Restrepo BI, Fisher-Hoch SP, Pino PA, Salinas A, Rahbar MH, Mora F, Cortes-Penfield N, McCormick JB. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis 2008, 47:634-641. 10.1086/590565, 2900313, 18652554.
71. Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies?. J Clin Epidemiol 1997, 50:223-229. 10.1016/S0895-4356(96)00360-5, 9120519.